Alpha-hemolysin, Gamma-hemolysin AB, Gamma-hemolysin CB, Panton-Valentine leukocidin, Leukocidin ED, and Leukocidin GH (Alpha-hemolysin (Hla), Gamma-hemolysin AB (HlgAB), Gamma-hemolysin CB (HlgCB), Panton-Valentine leukocidin (PVL), Leukocidin ED (LukED), Leukocidin GH (LukGH))

The listed molecules are major pore-forming cytotoxins produced by *Staphylococcus aureus*. Alpha-hemolysin (Hla) forms a heptameric β-barrel pore on host cell membranes, leading to rapid osmotic lysis, especially of red blood cells and epithelial cells. Gamma-hemolysin and various leukocidins (PVL, LukED, LukGH) are bicomponent toxins that consist of pairs of subunits assembling on immune cell membranes, forming octameric β-barrel pores. These toxins destroy leukocytes and disrupt immune defense, playing a critical role in severe and invasive *S. aureus* infections including necrotizing pneumonia and skin abscesses. Structurally, all share a similar β-barrel pore assembly, yet show different cell tropisms and species specificities. Their presence is associated with increased disease severity and poor outcomes in affected patients, making them important therapeutic targets for neutralizing anti-virulence therapies.

Other names

Staphylococcal pore-forming toxinsStaphylococcal cytolysins*S. aureus* hemolysins/leukocidinsAlpha-toxin (for alpha-hemolysin)PVL (for Panton-Valentine leukocidin)LukS-PV, LukF-PV (for PVL subunits)HlgA/HlgB (gamma-hemolysin AB)HlgC/HlgB (gamma-hemolysin CB)LukEDLukGH

Drugs/antibodies act by neutralizing toxins, blocking binding to host cell receptors (like ADAM10 for alpha-hemolysin), or preventing pore formation. Immunotherapies may also enhance clearance of toxin-producing bacteria.